Arrowhead (ARWR) is down -12.2%, or -$8.34 to $60.11.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Arrowhead files automatic mixed securities shelf
- Arrowhead price target raised to $80 from $52 at RBC Capital
- Analyst Recommends Buy Rating for Arrowhead Pharmaceuticals Due to Promising Obesity Treatment Potential
- Arrowhead price target raised to $81 from $62 at BofA
- Cautious Optimism for Arrowhead Pharmaceuticals Amid Competitor’s Positive Obesity Treatment Data